# CAR-T Followed by Bispecific Antibodies

> **NCT04889716** · PHASE2 · RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Large B-cell Lymphoma
- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** mosunetuzumab
- **DRUG:** glofitamab
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT04889716
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889716, "CAR-T Followed by Bispecific Antibodies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04889716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*